India’s pharmaceutical industry, often dubbed the “pharmacy of the world,” is making strategic adjustments as global trade policies shift. With rising tariffs and increasing scrutiny in developed markets, Indian companies are diversifying their export strategies, focusing on semi-regulated markets in Africa, Latin America, and Southeast Asia, as well as strengthening ties with Russia and China.
Historically, India relied heavily on exporting to the US and EU, but regulatory barriers and price pressures are squeezing margins. By targeting emerging economies, Indian pharma companies hope to reduce reliance on a handful of developed markets. This approach is bolstered by India’s ability to produce high-quality generics at scale and lower costs.
A key challenge is India’s dependency on China for active pharmaceutical ingredients (APIs), which make up over 60% of its imports. The government is responding with a Production Linked Incentive (PLI) scheme to boost domestic API manufacturing, though progress remains uneven.
Meanwhile, consolidation is reshaping the sector. Torrent Pharma’s recent Rs 18,000 crore acquisition of JB Chemicals created India’s second-most valued pharma company. Mergers like these help companies scale globally while diversifying portfolios.
The outlook is mixed: opportunities abound in new markets, but India must balance supply chain risks, maintain quality, and invest in innovation. Still, by pivoting toward diversification, India is aiming to preserve its global edge while adapting to a volatile trade environment.
